Thank you, Mr. Chairman.
First of all, I would like to thank the finance committee members for inviting our association to appear today. I understand you received over 100 requests for appearances. We are pleased to be here to share our recommendations for fiscal measures that can improve Canada's productivity.
As you know, Rx & D is the national organization representing more than 50 research-based pharmaceutical companies in Canada and the 20,000 men and women who work for them. Averaging more than $1 billion a year in R & D investments, we are one of the most R & D-intensive industries in Canada, second only to the telecommunications sector.
As identified in Budget 2007 and in Advantage Canada documents, it is important to highlight that we were encouraged that the current government, following in the steps of the previous governments, recognizes the vital importance of science and technology research and innovation to the long-term growth and prosperity of our country's economy.
In this spirit, Rx&D would like to present two recommendations to the finance committee today. The first would be improvements related to the scientific research and experimental design tax credit.
First, we believe that it is very important to modernize and improve the Scientific Research and Experimental Development (SRED) Tax Incentive Program.
This SR and ED tax credit is a vital component of the overall investment climate for business in Canada. With targeted modifications, it could enrich this climate and provide valuable advantages in the crucial effort to stay ahead of current and future international competitors.
To this end, we recommend that the government broaden the definition of eligible SR and ED tax credits to include “research in the social sciences” so that it is better harmonized with the OECD definition. The current definition fails to recognize the integral role played by social sciences research in the application of health research carried out in Canada.
In a practical sense, if you have something that is happening in the lab and you're not sure it's going to work at the community level, I think that's a problem. We would like to see the definition in Canada expanded so we can make sure that what we're doing in a clinical setting will have greater application at the community level.
We'd also like to make the full amount of the SR and ED tax credit refundable for all biopharmaceutical start-ups, whether they're Canadian-controlled private corporations or not.
I trust that the committee will also hear from other stakeholders who provide recommendations that follow in the same line.
We know that research and development, particularly in the life sciences, is a global enterprise and that a number of multinational companies located in Canada are spending the billion dollars they spend every year on health research and development.
So that we can encourage a greater amount of foreign direct investment to this country, we suggest that by expanding the eligibility of the SR and ED tax credit to both Canadian-controlled private corporations and non-Canadian-controlled private corporations we would actually see an increase in the level of R and D conducted in this country and therefore an increase in productivity in the economy.
We also want to increase the annual expenditure limit to $10 million, from the current limit of $2 million that was established over 20 years ago.
The incentive that gave Canada a global edge on the SR and ED program has become dated. We strongly believe that Canada can make immediate changes to the credit that will benefit all industries and make a major contribution to the goal of fostering a more innovative and productive economy.
Our second recommendation supports the recommendations made by the Auditor General in 2006 regarding Health Canada. We recommend that funding to Health Canada remain stable and predictable considering the ever-increasing pressures the department is experiencing and in the North American smart regulations context.
It should be noted that Health Canada has made improvements regarding drug approvals and it has helped the department move closer to internationally competitive performance targets. Without a sustainable, long-term funding model, however, Health Canada's ability to maintain high-quality, timely reviews will be compromised.
R and D in Canada, as in Europe, has stagnated in recent years, while emerging economies account for an increasing share of global R and D activity. While Canada's knowledge-based economy has a number of strengths to draw upon, our ability to translate these strengths into investments that bring tangible benefits to Canadians depends greatly on an efficient regulatory system and the business climate in which we operate.
As you develop your recommendations, we ask you to consider how they can support the policy objectives in the federal Science and Technology Framework and in Health Canada's Blueprint for Renewal.
We strongly believe that political leaders have made important strides in unleashing R and D in Canada, and we would like to see this continued with targeted fiscal measures that will help Canada increase its ability to attract the over $100 billion in life sciences investment that takes place in the world today.
We feel that what we are proposing with regard to the SR and ED tax credit will help businesses, large and small, and not only businesses within the innovative pharmaceutical industry but businesses that conduct intensive R and D activities, and it will also help Canada and Canadians become more healthy and prosperous, from both an economic and a social point of view. These recommendations are just one component of creating a stable and predictable operating environment for business in Canada and will also help attract more business to Canada.
Thank you.